US 3753988A
· Rodway et al.
· 1973
[cited by applicant]
US 4522811A
· Eppstein et al.
· 1985
[cited by applicant]
US 5089494A
· Iwase et al.
· 1992
[cited by applicant]
US 5324727A
· Iwase et al.
· 1994
[cited by applicant]
US 5565472A
· Hamanaka
· 1996
[cited by applicant]
US 5621027A
· Roschger et al.
· 1997
[cited by applicant]
US 5763263A
· Dehlinger
· 1998
[cited by applicant]
US 5849741A
· Watanabe et al.
· 1998
[cited by applicant]
US 6114530A
· Yuan et al.
· 2000
[cited by applicant]
US 6218392B1
· Watanabe et al.
· 2001
[cited by applicant]
US 6288064B1
· Watanabe et al.
· 2001
[cited by applicant]
US 6316438B1
· Yu et al.
· 2001
[cited by applicant]
US 6353103B1
· Yuan et al.
· 2002
[cited by applicant]
US 6486158B1
· Wang et al.
· 2002
[cited by applicant]
US 6858624B2
· Hagen et al.
· 2005
[cited by applicant]
US 7087621B2
· Sang et al.
· 2006
[cited by applicant]
US 7560551B2
· Cee et al.
· 2009
[cited by applicant]
US 7666898B2
· Chang et al.
· 2010
[cited by applicant]
US 7790882B2
· Carreira
· 2010
[cited by applicant]
US 8067608B2
· Beachy et al.
· 2011
[cited by applicant]
US 8106066B2
· Schumacher et al.
· 2012
[cited by applicant]
US 8318793B2
· Turner et al.
· 2012
[cited by applicant]
US 8329698B2
· Cravo et al.
· 2012
[cited by applicant]
US 8338591B2
· Yoon et al.
· 2012
[cited by applicant]
US 8445473B2
· Wang et al.
· 2013
[cited by applicant]
US 8575183B2
· Cushing et al.
· 2013
[cited by applicant]
US 8642660B2
· Goldfarb
· 2014
[cited by applicant]
US 8658801B2
· Loiseleur et al.
· 2014
[cited by applicant]
US 8674097B2
· Cravo et al.
· 2014
[cited by applicant]
US 8791113B2
· Dorsch et al.
· 2014
[cited by applicant]
US 8846673B2
· Duan et al.
· 2014
[cited by applicant]
US 8895587B2
· Cassayre et al.
· 2014
[cited by applicant]
US 8912202B2
· Staehle et al.
· 2014
[cited by applicant]
US 8932557B2
· Chen et al.
· 2015
[cited by applicant]
US 8940724B2
· Cushing et al.
· 2015
[cited by applicant]
US 8980929B2
· Hicks et al.
· 2015
[cited by applicant]
US 8981087B2
· Shuttleworth et al.
· 2015
[cited by applicant]
US 9023490B2
· Che
· 2015
[cited by applicant]
US 9198907B2
· Lahser et al.
· 2015
[cited by applicant]
US 9266855B2
· Turner et al.
· 2016
[cited by applicant]
US 9309231B2
· Zhang et al.
· 2016
[cited by applicant]
US 9458168B2
· Trzupek et al.
· 2016
[cited by applicant]
US 9481672B2
· Fürstner et al.
· 2016
[cited by applicant]
US 9593108B2
· MacCoss et al.
· 2017
[cited by applicant]
US 9598417B2
· Haßfeld et al.
· 2017
[cited by applicant]
US 9617279B1
· Zhang
· 2017
[cited by applicant]
US 9675073B2
· Rawal et al.
· 2017
[cited by applicant]
US 9765039B2
· Fairfax et al.
· 2017
[cited by applicant]
US 9879022B2
· Trzupek et al.
· 2018
[cited by applicant]
US 9949977B2
· Fürstner et al.
· 2018
[cited by applicant]
US 9949978B2
· Fürstner et al.
· 2018
[cited by applicant]
US 20030124053A1
· Barrett et al.
· 2003
[cited by applicant]
US 20040242886A1
· Gupta et al.
· 2004
[cited by applicant]
US 20060156485A1
· Lim
· 2006
[cited by applicant]
US 20060276505A1
· Nelson et al.
· 2006
[cited by applicant]
US 20070179123A1
· Chiang et al.
· 2007
[cited by applicant]
US 20090082358A1
· Nishimura et al.
· 2009
[cited by applicant]
US 20090105266A1
· Glatthar et al.
· 2009
[cited by applicant]
US 20090124624A1
· Augereau et al.
· 2009
[cited by applicant]
US 20090239896A1
· Chang et al.
· 2009
[cited by applicant]
US 20090318476A1
· Ramtohul
· 2009
[cited by applicant]
US 20110124661A1
· Brnardic et al.
· 2011
[cited by applicant]
US 20110150833A1
· Feng et al.
· 2011
[cited by applicant]
US 20110152246A1
· Buckman et al.
· 2011
[cited by applicant]
US 20110178117A1
· Converso et al.
· 2011
[cited by applicant]
US 20110218211A1
· Bergeron et al.
· 2011
[cited by applicant]
US 20120030841A1
· Koerber et al.
· 2012
[cited by applicant]
US 20130079342A1
· Dransfield et al.
· 2013
[cited by applicant]
US 20130165440A1
· Anand et al.
· 2013
[cited by applicant]
US 20140107151A1
· Goldstein et al.
· 2014
[cited by applicant]
US 20140194480A1
· Hoppe et al.
· 2014
[cited by applicant]
US 20160194320A1
· Turner et al.
· 2016
[cited by applicant]
US 20160237059A1
· Straub et al.
· 2016
[cited by applicant]
US 20180093956A1
· Dai et al.
· 2018
[cited by applicant]
US 20180215731A1
· Crew et al.
· 2018
[cited by applicant]
US 20200061063A1
· Fürstner et al.
· 2020
[cited by applicant]
US 20210221808A1
· Chen et al.
· 2021
[cited by applicant]
US 20220340567A1
· Dorich et al.
· 2022
[cited by applicant]
US 20230212152A1
· Arnold et al.
· 2023
[cited by applicant]
US 20240158396A1
· Dorich et al.
· 2024
[cited by applicant]
US 20240239808A1
· Berry et al.
· 2024
[cited by applicant]
US 20240368160A1
· Dorich et al.
· 2024
[cited by applicant]
US 20240409540A1
· Dorich et al.
· 2024
[cited by applicant]
CN 1984904A
· 2007
[cited by applicant]
CN 103992311A
· 2014
[cited by applicant]
CN 108697709A
· 2018
[cited by applicant]
CN 110563722A
· 2019
[cited by applicant]
CN 111093773A
· 2020
[cited by applicant]
CN 202011562172
· 2020
[cited by applicant]
CN 2021100906872
· 2021
[cited by applicant]
CN 2021105927697
· 2021
[cited by applicant]
CN 2021106294390
· 2021
[cited by applicant]
CN 2021107915923
· 2021
[cited by applicant]
CN 2021108434969
· 2021
[cited by applicant]
CN 2021101726650
· 2021
[cited by applicant]
CN 2021109400137
· 2021
[cited by applicant]
CN 202110940018
· 2021
[cited by applicant]
CN 202210015181
· 2022
[cited by applicant]
CN 2022100156993
· 2022
[cited by applicant]
CN 115417856A
· 2022
[cited by applicant]
CN 116726020A
· 2023
[cited by applicant]
CN 116789674A
· 2023
[cited by applicant]
CN 116969920A
· 2023
[cited by applicant]
CN 118056822A
· 2024
[cited by applicant]
EP 0449203B1
· 1994
[cited by applicant]
EP 0683212A1
· 1995
[cited by applicant]
EP 0623112B1
· 1998
[cited by applicant]
EP 0722936B1
· 2004
[cited by applicant]
EP 1451202B1
· 2008
[cited by applicant]
EP 1984354B1
· 2009
[cited by applicant]
EP 2285786B1
· 2013
[cited by applicant]
EP 2411379B1
· 2014
[cited by applicant]
EP 1984353B1
· 2015
[cited by applicant]
EP 2445886B1
· 2016
[cited by applicant]
EP 2847190B1
· 2016
[cited by applicant]
EP 2571876B1
· 2016
[cited by applicant]
EP 2742029B1
· 2016
[cited by applicant]
EP 2621914B1
· 2016
[cited by applicant]
EP 2459543B1
· 2017
[cited by applicant]
EP 3045456B1
· 2017
[cited by applicant]
EP 2880030B1
· 2018
[cited by applicant]
EP 2709983B1
· 2018
[cited by applicant]
EP 3126330B1
· 2019
[cited by applicant]
EP 3066100B1
· 2019
[cited by applicant]
EP 3536685A1
· 2019
[cited by applicant]
EP 3553049A1
· 2019
[cited by applicant]
EP 2585461B1
· 2020
[cited by applicant]
EP 3604298A1
· 2020
[cited by applicant]
EP 3613751A1
· 2020
[cited by applicant]
EP 2852572B1
· 2020
[cited by applicant]
EP 3237419B1
· 2021
[cited by applicant]
GB 1303061A
· 1973
[cited by applicant]
GB 2063249A
· 1981
[cited by applicant]
HK 20098858
· 2024
[cited by applicant]
JP H03284669A
· 1991
[cited by applicant]
JP H06135938A
· 1994
[cited by applicant]
JP 2009120486A
· 2009
[cited by applicant]
WO WO8911279A1
· 1989
[cited by applicant]
WO WO9315058A1
· 1993
[cited by applicant]
WO WO9605176A1
· 1996
[cited by applicant]
WO WO9807430A1
· 1998
[cited by applicant]
WO WO0056719A1
· 2000
[cited by applicant]
WO WO03045967A1
· 2003
[cited by applicant]
WO WO2004099158A1
· 2004
[cited by applicant]
WO WO2005016000A1
· 2005
[cited by applicant]
WO WO2005033288A2
· 2005
[cited by applicant]
WO WO2006004589A2
· 2006
[cited by applicant]
WO WO2006090273A2
· 2006
[cited by applicant]
WO WO2006110516A1
· 2006
[cited by applicant]
WO WO2007038367A1
· 2007
[cited by applicant]
WO WO2007056184A2
· 2007
[cited by applicant]
WO WO2007056281A2
· 2007
[cited by applicant]
WO WO2007056580A2
· 2007
[cited by applicant]
WO WO2007087276A1
· 2007
[cited by applicant]
WO WO2007093402A1
· 2007
[cited by applicant]
WO WO2008017161A1
· 2008
[cited by applicant]
WO WO2008128968A1
· 2008
[cited by applicant]
WO WO2008137084A2
· 2008
[cited by applicant]
WO WO2009035568A1
· 2009
[cited by applicant]
WO WO2009038812A1
· 2009
[cited by applicant]
WO WO2009079008A1
· 2009
[cited by applicant]
WO WO2009086303A2
· 2009
[cited by applicant]
WO WO2009126947A2
· 2009
[cited by applicant]
WO WO2009140163A1
· 2009
[cited by applicant]
WO WO2009152909A1
· 2009
[cited by applicant]
WO WO2009157386A1
· 2009
[cited by applicant]
WO WO2010021934A2
· 2010
[cited by applicant]
WO WO2010036544A1
· 2010
[cited by applicant]
WO WO2010101949A1
· 2010
[cited by applicant]
WO WO2010109005A1
· 2010
[cited by applicant]
WO WO2010112545A1
· 2010
[cited by applicant]
WO WO2010117935A1
· 2010
[cited by applicant]
WO WO2010117936A1
· 2010
[cited by applicant]
WO WO2010151791A1
· 2010
[cited by applicant]
WO WO2011012883A1
· 2011
[cited by applicant]
WO WO2011019780A1
· 2011
[cited by applicant]
WO WO2011075607A1
· 2011
[cited by applicant]
WO WO2011123751A2
· 2011
[cited by applicant]
WO WO2011146358A1
· 2011
[cited by applicant]
WO WO2012000595A1
· 2012
[cited by applicant]
WO WO2012003264A1
· 2012
[cited by applicant]
WO WO2012037132A1
· 2012
[cited by applicant]
WO WO2012041814A1
· 2012
[cited by applicant]
WO WO2012156400A1
· 2012
[cited by applicant]
WO WO2012158810A1
· 2012
[cited by applicant]
WO WO2013020622A1
· 2013
[cited by applicant]
WO WO2013026939A1
· 2013
[cited by applicant]
WO WO2013078254A1
· 2013
[cited by applicant]
WO WO2013167495A1
· 2013
[cited by applicant]
WO WO2013176698A1
· 2013
[cited by applicant]
WO WO2014019344A1
· 2014
[cited by applicant]
WO WO2014079935A1
· 2014
[cited by applicant]
WO WO2014079941A1
· 2014
[cited by applicant]
WO WO2014080291A2
· 2014
[cited by applicant]
WO WO2014086737A1
· 2014
[cited by applicant]
WO WO2014131315A1
· 2014
[cited by applicant]
WO WO2015001348A1
· 2015
[cited by applicant]
WO WO2015036560A1
· 2015
[cited by applicant]
WO WO2015067549A1
· 2015
[cited by applicant]
WO WO2015150995A1
· 2015
[cited by applicant]
WO WO2016086200A9
· 2016
[cited by applicant]
WO WO2016103037A1
· 2016
[cited by applicant]
WO WO2016131098A1
· 2016
[cited by applicant]
WO WO2017100726A1
· 2017
[cited by applicant]
WO WO2017136871A1
· 2017
[cited by applicant]
WO WO2017140778A1
· 2017
[cited by applicant]
WO WO2017144341A1
· 2017
[cited by applicant]
WO WO2017184604A1
· 2017
[cited by applicant]
WO WO2017184623A1
· 2017
[cited by applicant]
WO WO2017184624A1
· 2017
[cited by applicant]
WO WO2018015445A1
· 2018
[cited by applicant]
WO WO2018031680A1
· 2018
[cited by applicant]
WO WO2018080216A1
· 2018
[cited by applicant]
WO WO2018138050A1
· 2018
[cited by applicant]
WO WO2018144649A1
· 2018
[cited by applicant]
WO WO2018172925A1
· 2018
[cited by applicant]
WO WO2018174678A1
· 2018
[cited by applicant]
WO WO2018217651A1
· 2018
[cited by applicant]
WO WO2018218071A1
· 2018
[cited by applicant]
WO WO2018221433A1
· 2018
[cited by applicant]
WO WO2019017741A1
· 2019
[cited by applicant]
WO WO2019038215A1
· 2019
[cited by applicant]
WO WO2019223548A1
· 2019
[cited by applicant]
WO WO2020021015A1
· 2020
[cited by applicant]
WO WO2020163248A1
· 2020
[cited by applicant]
WO WO2020234715A1
· 2020
[cited by applicant]
WO WO2021193897A1
· 2021
[cited by applicant]
WO WO2021239885A1
· 2021
[cited by applicant]
WO WO2022135567A1
· 2022
[cited by applicant]
WO WO2022166890A1
· 2022
[cited by applicant]
WO WO2022216971A1
· 2022
[cited by applicant]
WO WO2022229315A1
· 2022
[cited by applicant]
WO WO2022230912A1
· 2022
[cited by applicant]
WO WO2022238347A1
· 2022
[cited by applicant]
WO WO2022253326A1
· 2022
[cited by applicant]
WO WO2022253936A1
· 2022
[cited by applicant]
WO WO2023003002A1
· 2023
[cited by applicant]
WO WO2023275366A1
· 2023
[cited by applicant]
WO WO2023278438A1
· 2023
[cited by applicant]
WO WO2023026222A1
· 2023
[cited by applicant]
WO WO2023028534A1
· 2023
[cited by applicant]
WO WO2023028536A1
· 2023
[cited by applicant]
WO WO2023066377A1
· 2023
[cited by applicant]
WO WO2023066825A1
· 2023
[cited by applicant]
WO WO2023088856A1
· 2023
[cited by applicant]
WO WO2023088987A1
· 2023
[cited by applicant]
WO WO2023129987A1
· 2023
[cited by applicant]
WO WO2023131277A1
· 2023
[cited by applicant]
WO 2023183943
· 2023
[cited by examiner]
WO WO2023178099A1
· 2023
[cited by applicant]
WO WO2023183943A1
· 2023
[cited by examiner]
WO WO2023186020A1
· 2023
[cited by applicant]
WO WO2023194964A1
· 2023
[cited by applicant]
WO WO2023220408A1
· 2023
[cited by applicant]
WO WO2023232917A1
· 2023
[cited by applicant]
WO WO2024006559A1
· 2024
[cited by applicant]
WO WO2024012551A1
· 2024
[cited by applicant]
WO WO2024013395A1
· 2024
[cited by applicant]
WO WO2024017924A1
· 2024
[cited by applicant]
WO WO2024023266A1
· 2024
[cited by applicant]
WO WO2024028782A1
· 2024
[cited by applicant]
WO WO2024033845A1
· 2024
[cited by applicant]
WO WO2024041460A1
· 2024
[cited by applicant]
WO WO2024064245A1
· 2024
[cited by applicant]
WO WO2024090469A1
· 2024
[cited by applicant]
WO WO2024094150A1
· 2024
[cited by applicant]
WO WO2024094185A1
· 2024
[cited by applicant]
WO WO2024097598A1
· 2024
[cited by applicant]
WO WO2024097629A1
· 2024
[cited by applicant]
WO WO2024099992A1
· 2024
[cited by applicant]
WO WO2024099993A1
· 2024
[cited by applicant]
WO WO2024099996A1
· 2024
[cited by applicant]
WO WO2024109922A1
· 2024
[cited by applicant]
WO WO2024121086A1
· 2024
[cited by applicant]
WO WO2024121184A1
· 2024
[cited by applicant]
WO WO2024137319A1
· 2024
[cited by applicant]
WO WO2024138045A1
· 2024
[cited by applicant]
WO WO2024140704A1
· 2024
[cited by applicant]
WO WO2024140824A1
· 2024
[cited by applicant]
WO WO2024141535A1
· 2024
[cited by applicant]
WO WO2024145623A1
· 2024
[cited by applicant]
WO WO2024148029A2
· 2024
[cited by applicant]
WO WO2024160690A1
· 2024
[cited by applicant]
WO WO2024160691A1
· 2024
[cited by applicant]
WO WO2024160692A1
· 2024
[cited by applicant]
WO WO2024160693A1
· 2024
[cited by applicant]
WO WO2024160694A1
· 2024
[cited by applicant]
WO WO2025059481A1
· 2025
[cited by applicant]
Co-pending U.S. Appl. No. 18/799,636, inventors Dorich; Stephane et al., filed Aug. 9, 2024.
[cited by applicant]
Database Registry No. RN 2060799-65-5, “Pyrido[2,3-d]pyridazin-8-a:mine, 5-(5-bromo-2-thienyl)-N-(1-methylethyl)-” (CA Index Name). STN, Chemical Abstracts Service; entered Jan. 29, 2017; 1 printed page.
[cited by applicant]
Database Registry No. RN 2062164-56-9, “Pyrido[2,3-d]pyridazin-8-amine, N-(l-methylethyl)-5-[5-(5-methyl-2-pyridinyl)-2-thienyl]-)” (CA Index Name). STN, Chemical Abstracts Service; entered Jan. 31, 2017; 1 printed page.
[cited by applicant]
Database Registry No. RN 2062164-57-0, Pyrido[2,3-d]pyridazin-8-amine, N-(l-methylethyl)-5-[5-(5-methyl-2-pyridinyl)-2-thienyl]-, hydrochloride (1:1) (CA Index Name). STN, Chemical Abstracts Service; entered Jan. 31, 20…
[cited by applicant]
Alikhan et al., Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. Apr. 2009;60(4):539-561; quiz 562-563. doi: 10.1016/j.jaad.2008.11.911.
[cited by applicant]
Allen et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med. May 10, 2010;207(5):1045-56. doi: 10.1084/jem.20100050. Epub Apr. 12, 2010.
[cited by applicant]
Alsenz et al. “High throughput solubility measurement in drug discovery and development” Adv Drug Deliv. Rev. (2007); 59(7):546-567.
[cited by applicant]
Amsler et al. The inflammasome as a target of modulation by DNA viruses. Future Virol. Apr. 1, 2013;8(4):357-370. doi: 10.2217/fvl.13.22.
[cited by applicant]
Artlett et al. The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis. Arthritis Rheum. Nov. 2011;63(11):3563-74. doi: 10.1002/art.30568.
[cited by applicant]
Baldwin et al. Inhibiting the Inflammasome: A Chemical Perspective. J Med Chem. Mar. 10, 2016;59(5):1691-710. doi: 10.1021/acs.jmedchem.5b01091.
[cited by applicant]
Basiorka et al. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood. Dec. 22, 2016;128(25):2960-2975. doi: 10.1182/blood-2016-07-730556. Epub Oct. 13, 2016.
[cited by applicant]
Behalo, M.S. et al. (Nov. 2017) Synthesis of Novel Phthalazine Derivatives as Potential Anticancer and Antioxidant Agents Based on 1-Chloro-4-(4-phenoxyphenyl)phthalazine. J Heterocyclic Chem. 54(6):3591-3599, DOI: 10.1…
[cited by applicant]
Bertoni et al. “A novel knock-in mouse model of cryopyrin-associated periodic syndromes with development of amyloidosis: therapeutic efficacy of proton pump inhibitors” J. Allergy Clin. Immunol. (2020); 145:368-378e13.
[cited by applicant]
Braddock et al. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov. Apr. 2004;3(4):330-9. doi: 10.1038/nrd1342.
[cited by applicant]
Byrne et al. “Empaglifozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure” Circ. Heart Fail. (2020); 13(1)…
[cited by applicant]
Chakraborty et al. “NLRP3 inflammasome in traumatic brain injury: Its implication in the disease pathophysiology and potential as a therapeutic target” Life Sciences (2023); 314(121352):1-8.
[cited by applicant]
Chen, P. et al. “Stem cells from human exfoliated deciduous teeth alleviate liver cirrhosis via inhibition of Gasdermin D-executed hepatocyte pyroptosis” Front. Immunol. (2022); 13(860225):1-12.
[cited by applicant]
Chen, Y. et al. “The NLRP3 inflammasome: contributions to inflammation-related diseases” Cellular & Molecular Biology Letters (2023); 28:51, 27 pages.
[cited by applicant]
Cheng, J. et al. “Microglial autophagy defect causes Parkinson disease-like symptoms by accelerating inflammasome activation in mice” Autophagy (2020); 16(12):2193-2205.
[cited by applicant]
Cheung A.K., et al., “Discovery of Small Molecule Splicing Modulators of Survival Motor Neuron-2 (SMN2) for the Treatment of Spinal Muscular Atrophy (SMA),” Journal of Medicinal Chemistry, 2018, vol. 61, pp. 11021-11036.
[cited by applicant]
Cho et al. “Autophagy in microglia degrades extracellular beta-amyloid fibrils and regulates the NLRP3 inflammasome” Autophagy (2014); 10:1761-1775.
[cited by applicant]
Coll, R. C. et al. “A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases” Nature Medicine, 21(3):248-255; including “Online Methods”, 2 pages (2015).
[cited by applicant]
Colotta, V. et al. (1994) Synthesis and structure-activity relationships of 1-aminophthalazinium salts as GABAA receptor antagonists. 29(2):95-105, DOI: 10.1016/0223-5234(94)90205-4.
[cited by applicant]
Cook et al., The NLRP3 inflammasome, a target for therapy in diverse disease states. Eur J Immunol. Mar. 2010;40(3):631-634. doi: 10.1002/eji.200940162.
[cited by applicant]
Co-pending U.S. Appl. No. 17/528,928, inventors Stephane; Dorich et al., filed Nov. 17, 2021.
[cited by applicant]
Co-pending U.S. Appl. No. 17/679,898, inventors Dorich; Stéphane et al., filed Feb. 24, 2022.
[cited by applicant]
Co-pending U.S. Appl. No. 17/704,983, inventors Dorich; Stéphane et al., filed Mar. 25, 2022.
[cited by applicant]
Co-pending U.S. Appl. No. 17/974,342, inventors Dorich; Stéphane et al., filed Oct. 26, 2022.
[cited by applicant]
Co-pending U.S. Appl. No. 17/984,018, inventors Dorich; Stéphane et al., filed Nov. 9, 2022.
[cited by applicant]
Co-pending U.S. Appl. No. 18/190,920, inventors Dorich; Stephane et al., filed Mar. 27, 2023.
[cited by applicant]
Co-pending U.S. Appl. No. 18/480,164, inventors Stéphane; Dorich et al., filed Oct. 3, 2023.
[cited by applicant]
Co-pending U.S. Appl. No. 18/480,925, inventors Stéphane; Dorich et al., filed Oct. 4, 2023.
[cited by applicant]
Co-pending U.S. Appl. No. 18/534,906, inventors Dorich; Stephane et al., filed Dec. 11, 2023.
[cited by applicant]
Co-pending U.S. Appl. No. 18/763,210, inventors Dorich:Stephane et al., filed Jul. 3, 2024.
[cited by applicant]
Co-pending U.S. Appl. No. 18/763,243, inventors Dorich; Stephane et al., filed Jul. 3, 2024.
[cited by applicant]
Co-pending U.S. Appl. No. 18/763,258, inventors Dorich:Stephane et al., filed Jul. 3, 2024.
[cited by applicant]
Co-pending U.S. Appl. No. 18/763,277, inventors Dorich; Stephane et al., filed Jul. 3, 2024.
[cited by applicant]
Co-pending U.S. Appl. No. 18/763,302, inventors Dorich; Stephane et al., filed Jul. 3, 2024.
[cited by applicant]
Corcoran et al. “Pharmacological inhibition of the nod-like receptor family pyrin domain containing 3 inflammasome with MCC950” Pharmacological Reviews (2021); 73(3):968-1000.
[cited by applicant]
Database Registry No. RN 1018067-04-3, “3-Pyridazinamine, 6-(4-chlorophenyl)-N-[(tetrahydro-2-furanyl)methyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Apr. 29, 2008; 1 printed page.
[cited by applicant]
Database Registry No. RN 1018166-04-5, “3-Pyridazinamine, 6-(4-bromophenyl)-N-[(tetrahydro-2-furanyl)methyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Apr. 29, 2008; 1 printed page.
[cited by applicant]
Database Registry No. RN 1027552-60-8, “Pyrido[3,4-d]pyridazin-4-amine, 7-(3-methyl-2-pyridinyl)-1-[4-(trifluoromethyl)phenyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Jun. 12, 2008; 1 printed page.
[cited by applicant]
Database Registry No. RN1002033-19-3, “1-Phthalazinamine, 4-(4-methylphenyl)-N-[2-(4-morpholinyl)ethyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Feb. 7, 2008; 1 printed page.
[cited by applicant]
Database Registry No. RN1078602-84-2, “1-Phthalazinamine, N-[2-(4-morpholinyl)ethyl]-4-phenyl-, ethanedioate (1:1)” (CA Index Name). STN, Chemical Abstracts Service; entered Dec. 2, 2008; 1 printed page.
[cited by applicant]
Database Registry No. RN1090015-30-7, “1-Phthalazinamine, 4-(4-fluorophenyl)-N-[2-methyl-2-(4-morpholinyl)propyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Dec. 25, 2008; 1 printed page.
[cited by applicant]
Database Registry No. RN1090983-56-4, “1-Phthalazinamine, 4-(4-fluorophenyl)-N-[2-(4-methoxyphenyl)-2-(4-morpholinyl)ethyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Dec. 28, 2008; 1 printed page.
[cited by applicant]
Database Registry No. RN1135019-11-2, “1-Phthalazinamine, 4-(3,4-dimethylphenyl)-N-[2-(4-morpholinyl)ethyl]-, ethanedioate (1:2)” (CA Index Name). STN, Chemical Abstracts Service; entered Apr. 15, 2009; 1 printed page.
[cited by applicant]
Database Registry No. RN1181498-12-3, “Benzamide, 4-[4-(cyclopentylamino)-1-phthalazinyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Sep. 9, 2009; 1 printed page.
[cited by applicant]
Database Registry No. RN1217112-04-3, “1-Phthalazinamine, 4-(4-methylphenyl)-N-[2-(4-morpholinyl)ethyl]-, ethanedioate (1:2)” (CA Index Name). STN, Chemical Abstracts Service; entered Apr. 6, 2010; 1 printed page.
[cited by applicant]
Database Registry No. RN1267866-53-4, “1-Phthalazinamine, 4-(4-fluorophenyl)-N-3-pyrrolidinyl-” (CA Index Name). STN, Chemical Abstracts Service; entered Mar. 10, 2011; 1 printed page.
[cited by applicant]
Database Registry No. RN1310214-26-6, “1-Phthalazinamine, 4-(4-methylphenyl)-N-3-pyrrolidinyl-” (CA Index Name). STN, Chemical Abstracts Service; entered Jun. 23, 2011; 1 printed page.
[cited by applicant]
Database Registry No. RN1340893-35-7, “1-Phthalazinamine, 4-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-N-[2-(4-morpholinyl)ethyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Nov. 4, 2011; 1 printed page.
[cited by applicant]
Database Registry No. RN1340906-77-5, “1-Phthalazinamine, 4-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-N-[2-(4-morpholinyl)ethyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Nov. 4, 2011; 1 printed page.
[cited by applicant]
Database Registry No. RN1340993-30-7, “1-Phthalazinamine, N-[2-(4-morpholinyl)ethyl]-4-(3-phenyl-1,2,4-oxadiazol-5-yl)-” (CA Index Name). STN, Chemical Abstracts Service; entered Nov. 4, 2011; 1 printed page.
[cited by applicant]
Database Registry No. RN1351271-90-3, “3-Pyridazinamine, N-(l-methylethyl)-6-(1,2,3,4-tetrahydro-5-isoquinolinyl)-” (CA Index Name). STN, Chemical Abstracts Service; entered Dec. 19, 2011; 1 printed page.
[cited by applicant]
Database Registry No. RN1482843-77-5, “1-Naphthalenol, 2-[6-(propylamino)-3-pyridazinyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Nov. 28, 2013; 1 printed page.
[cited by applicant]
Database Registry No. RN1485079-65-9, “1-Naphthalenol, 2-[6-(ethylamino)-3-pyridazinyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Dec. 2, 2013; 1 printed page.
[cited by applicant]
Database Registry No. RN1488322-94-6, “1-Phthalazinamine, 4-(2-methoxyphenyl)-N-methyl-” (CA Index Name). STN, Chemical Abstracts Service; entered Dec. 5, 2013; 1 printed page.
[cited by applicant]
Database Registry No. RN1494117-54-2, “1-Phthalazinamine, 4-(2-methoxy-5-methylphenyl)-Nmethyl-” (CA Index Name). STN, Chemical Abstracts Service; entered Dec. 13, 2013; 1 printed page.
[cited by applicant]
Database Registry No. RN1496330-00-7, “1-Phthalazinamine, 4-(5-fluoro-2-methoxyphenyl)-Nmethyl-” (CA Index Name). STN, Chemical Abstracts Service; entered Dec. 16, 2013; 1 printed page.
[cited by applicant]
Database Registry No. RN1562335-33-4, “2,7-Naphthalenediol, 3-[6-[(2,2,6,6-tetramethyl-4-piperidinyl)oxy]-3-pyridazinyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Mar. 4, 2014; 1 printed page.
[cited by applicant]
Database Registry No. RN1562335-37-8, “2,7-Naphthalenediol, 3-[6-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-3-pyridazinyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Mar. 4, 2014; 1 printed page.
[cited by applicant]
Database Registry No. RN1647113-18-5, “6-Isoquinolinol, 7-[6-[(2,2,6,6-tetramethyl-4-piperidinyl)oxy]-3-pyridazinyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Feb. 13, 2015; 1 printed page.
[cited by applicant]
Database Registry No. RN1647113-19-6, “Isoquinoline, 6-methoxy-7-[6-[(2,2,6,6-tetramethyl-4-piperidinyl)oxy]-3-pyridazinyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Feb. 13, 2015; 1 printed page.
[cited by applicant]
Database Registry No. RN1647116-09-3, “6-Isoquinolinol, 3-propyl-7-[6-[(2,2,6,6-tetramethyl-4-piperidinyl)oxy]-3-pyridazinyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Feb. 13, 2015; 1 printed page.
[cited by applicant]
Database Registry No. RN1647116-10-6, “6-Isoquinolinol, 3-(l-methylethyl)-7-[6-[(2,2,6,6-tetramethyl-4-piperidinyl)oxy]-3-pyridazinyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Feb. 13, 2015; 1 printed…
[cited by applicant]
Database Registry No. RN174542-71-3, “Phthalazine, 1-(4-methoxyphenyl)-4-(4-methylphenoxy)-” (CA Index Name). STN, Chemical Abstracts Service; entered Mar. 26, 1996; 1 printed page.
[cited by applicant]
Database Registry No. RN1892513-27-7, “Acetonitrile, 2-[[6-(5,6,7,8-tetrahydro-2-naphthalenyl)-3-pyridazinyl]amino]-” (CA Index Name). STN, Chemical Abstracts Service; entered Apr. 18, 2016; 1 printed page.
[cited by applicant]
Database Registry No. RN1893453-26-3, “3-Pyridazinamine, N-(l-methylethyl)-6-(2-naphthalenyl)-” (CA Index Name). STM, Chemical Abstracts Service; entered Apr. 20, 2016; 1 printed page.
[cited by applicant]
Database Registry No. RN2198981-59-6, “Cyclopentanecarboxylic acid, 3-hydroxy-4-[[4-(4-methoxyphenyl)-1-phthalazinyl]amino]-” (CA Index Name). STN, Chemical Abstracts Service; entered Mar. 26, 2018; 1 printed page.
[cited by applicant]
Database Registry No. RN2332630-59-6, Index Name Not yet Assigned. STN, Chemical Abstracts Service; entered Jun. 13, 2019; 1 printed page.
[cited by applicant]
Database Registry No. RN2344192-58-9, “3-Pyridazinamine, N-pentyl-6-(5,6,7,8-tetrahydro-2-naphthalenyl)-” (CA Index Name). STN, Chemical Abstracts Service; entered Jun. 24, 2019; 1 printed page.
[cited by applicant]
Database Registry No. RN296248-99-2, “4-Piperidinol, 1-[3-ethyl-9-[[2-(4-morpholinyl)ethyl]amino]-3Hpyrazolo[4′,3′:5,6]pyrido[3,4-d]pyridazin-6-yl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Oct. 17, 20…
[cited by applicant]
Database Registry No. RN30181-95-4, “1-Phthalazinamine, N-[2-(4-morpholinyl)ethyl]-4-phenyl-” (CA Index Name). STN, Chemical Abstracts Service; entered Nov. 16, 1984; 1 printed page.
[cited by applicant]
Database Registry No. RN312591-18-7, “1-Phthalazinamine, 4-(4-chlorophenyl)-N-[2-(4-morpholinyl)ethyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Jan. 3, 2001; 1 printed page.
[cited by applicant]
Database Registry No. RN361998-09-6, “1-Phthalazinamine, N-(3,4-dichlorophenyl)-4-(4-methoxyphenyl)-” (CA Index Name). STN, Chemical Abstracts Service; entered Oct. 14, 2001; 1 printed page.
[cited by applicant]
Database Registry No. RN447430-57-1, “1-Phthalazinamine, N-cyclohexyl-4-(3,4-dimethylphenyl)-” (CA Index Name). STN, Chemical Abstracts Service; entered Sep. 6, 2002; 1 printed page.
[cited by applicant]
Database Registry No. RN447430-58-2, “1-Phthalazinamine, N-cyclohexyl-4-(4-methylphenyl)-” (CA Index Name). STN, Chemical Abstracts Service; entered Sep. 6, 2002; 1 printed page.
[cited by applicant]